Terms: = Liver cancer AND B2M, P61769, 567, ENSG00000166710 AND Clinical Outcome
5 results:
1. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted cancer Therapy.
Wang T; Philippovich S; Mao J; Veedu RN
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546749
[TBL] [Abstract] [Full Text] [Related]
2. The Prediction of clinical outcome in Hepatocellular Carcinoma Based on a Six-Gene Metastasis Signature.
Yuan S; Wang J; Yang Y; Zhang J; Liu H; Xiao J; Xu Q; Huang X; Xiang B; Zhu S; Li L; Liu J; Liu L; Zhou W
Clin Cancer Res; 2017 Jan; 23(1):289-297. PubMed ID: 27449498
[TBL] [Abstract] [Full Text] [Related]
3. Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related liver Diseases.
Ouda SM; Khairy AM; Sorour AE; Mikhail MN
Asian Pac J Cancer Prev; 2015; 16(17):7825-9. PubMed ID: 26625805
[TBL] [Abstract] [Full Text] [Related]
4. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
[TBL] [Abstract] [Full Text] [Related]
